| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Blinatumomab |
| Brand | Blincyto® |
| Indication | Treatment of paediatric patients aged 1 year and older with Philadelphia chromosome negative B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation |
| Assessment Process | |
| Rapid review commissioned | 15/01/2019 |
| Rapid review completed | 30/01/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of blinatumomab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations; May 2019
